Shafrir and Raz bring up an interesting semantic question in a recent issue of Diabetologia [1] . Should diabetes mellitus be called diabetes lipidus because the basic metabolic aberration actually starts in lipid rather than in carbohydrate metabolism? The reason for being called mellitus might have been due to the fact that the sweetness of urine was easy to discover just by tasting, and biochemical measurement of glucose is still easier to do than of lipids.
This debate article highlights a fundamental problem: the effect of fat oxidation in the pathogenesis of insulin resistance, followed by diabetes. The regulation of such fat oxidation probably carries the key to understanding why and how diabetes develops.
If we look at prospective data there is no doubt that obesity is the dominant risk factor for developing diabetes. Is obesity associated with increased fat oxidation? Before this question can be answered, there is a very important distinction to be made, which is often forgotten. At the same degree of obesity in terms of total body-fat mass, there is now conclusive evidence that central obesity is much more closely associated with insulin resistance and is a more powerful risk factor for developing diabetes than peripheral obesity. In fact there is evidence that peripheral obesity, at least in moderate forms, might not be insulin resistant at all [2] . It is highly surprising that this now established finding is often neglected in the discussion on the pathogenesis of diabetes. This distinction is important from many aspects. For example, the remarkable difference in the risk of developing diabetes between central and peripheral obesity is probably hiding relevant information and clues for understanding the pathogenesis of diabetes. There must be some specific factor in central obesity which is diabetogenic, and which is not present in peripheral obesity. This difference is most likely the increased fat oxidation in central obesity.
Returning to the question of analysing the statistical power of various factors for developing insulin resistance and diabetes, obesity clearly occupies an important place. However, the subgroup of central obesity carries most of this burden, and is closely followed by the effect of NEFA turn over. The strongest determinant of insulin resistance is, however, the size of local, intracellular triglyceride pools in the liver and in muscles. This statistical analysis is compatible with the following chain of mechanistic events. Local intracellular triglyceride pools determine insulin resistance by furnishing excess substrate to lipid oxidation [3] . This is directly dependent on the influx of NEFA to these pools, which in turn is dependent on circulating NEFA concentrations. Concentrations of NEFA are clearly increased in central as compared with peripheral obesity [2] . This is probably why central obesity shows a much higher risk than peripheral obesity for developing insulin resistance and diabetes.
Consequently, why are NEFA increased in central obesity? Central depots are more easily mobilizable than peripheral depots [4] . This means that for any challenge of the lipid mobilizing system, more NEFA will flow out from central than peripheral depots. In addition, and perhaps more crucial, the important insulin controlling effects of lipid mobilization are less efficient in central than peripheral depots [4] .
Why then is excess fat directed to central depots? The effects of hormones are established in this event. The most clear cut example is the central fat distribution in states of hypercortisolism, an extreme example being Cushing's Syndrome. Cortisol stimulates the rate-limiting pathway for lipid uptake in fat cells, the lipoprotein lipase. Since glucocorticoid receptors have a higher density in central than other depots, the fat accumulation in conditions with increased cortisol will be preferentially central [4] .
In addition to this local fat accumulating action of cortisol, the lipid mobilization process is affected, both by facilitating the lipolytic process by "permissive" effects and by blunting the antilipolytic effect of insulin. The net effects then will be preferential fat accumulation in central depots, with an increased turnover, releasing increased NEFA into circulation. Sex steroid and growth hormones have in essence opposite effects and balance the effects of cortisol. A deficiency of these hormones then will have the net effect of an amplification of cortisol effects [4] .
The endocrine abnormalities described above have been found in central obesity [5] , and are due to an increased activity of the hypothalamic-pituitary-adrenal (HPA) axis with increased secretion of cortisol and, secondarily, inhibition of the central gonadal and growth hormone axes [6] . Several factors, known to activate the HPA axis have been identified in central obesity, including psychosocial and socioeconomic handicaps, probably predisposing to "stress" reactions, depressive and anxiety traits, alcohol and smoking [7] . In addition, central obesity is characterized by an increased activity of the other main "stress" axis, the sympathetic nervous system, which is to be expected because of both these major "stress" axes are usually activated simultaneously [6] . The sympathetic nervous system is the major stimulatory factor of lipolysis in humans [4] .
In summary, insulin resistance preceding diabetes starts with an interference by lipid oxidation on insulin effects. These observations make it possible to understand why central obesity carries a much higher risk for developing insulin resistance and diabetes than peripheral obesity. In central obesity a number of factors, each alone or in combination, activate the HPA axis, resulting in increased cortisol secretion, and inhibition of sex steroid and growth-hormone secretions. This di-
Author's reply
To the Editor: Dr. Per Bjorntorp rightly confirms our thesis that the basic metabolic derangements leading to diabetes originate in aberrations of lipid rather than carbohydrate metabolism and the augmented fat oxidation may be the key to understanding the development of diabetes.
He emphasises that obesity is the dominant factor leading to diabetes, maintaining that central rather than peripheral obesity is more closely associated with insulin resistance. Rightly so, this factor, often neglected in the understanding of the pathogenesis of Type 2 diabetes, most probably induces an increased mobilisation of fatty acids from central adipose tissue and accelerates fat oxidation by central viscera. However, even if the lipid supply to skeletal muscles may be a sequel of central obesity, the problem of hormonal regulation leading to preferential central fat deposition and release has to be fully resolved. The very fact of the increased size of abdominal adipocytes and the increased mass of the abdominal fat depot seems to enhance the fatty acid turnover along with their release. The activity of several lipid mobilising substances secreted from central adipose tissue can differ from those of peripheral adipose tissue and would be of major interest to know how to counteract their action and use this knowledge for the treatment of diabesity.
As explained in our article, we stress that the ectopic intramyocellular fat deposition is committed to eliciting insulin resistance, not necessarily directly related to obesity. It has yet to be determined whether the traffic of newly ingested fat is directed to muscles rather than to peripheral or central adipose tissues, or if it is following the growth of adipose tissues. Also, it is well known that in many cases obesity is secondary to insulin resistance rather than preceding it and muscle fat increment is likely to occur prior to obesity.
The accumulation of diacylglycerol in muscles as a result of increased triglyceride and fatty acyl-CoA turnover (during augmented local triglyceride synthesis and breakdown) leads to a negative loop in insulin signal transduction. This is due to PKC activation and alteration in components of the insulin signalling pathway by multisite serine phospohorylation. It remains to be fully elucidated how the muscle fat deposition is related to obesity, particularly abdominal fat accumulation, or how it is brought about by other hormonal factors and cytokines, including those secreted by adipose tissue itself. It is also important to establish what factors are responsible for the ineffective arrest of lipolysis in the central, compared with peripheral depots. It should also be remembered that long-term insulin resistance, associated with glucose intolerance, can involve fat inflow into beta cells with resultant secretory impairment.
With regard to the revision in diabetes nomenclature, we welcome the support of Dr. Bjorntorp for dropping the adjective "mellitus" from the name of diabetes as a first step. It is sufficient for now that we diagnose Type 1 and Type 2 diabetes without additional labels. These are markedly different diseases and require an exact definition. However, in the case of Type 2 diabetes, the development of which is overtly associated with deviations in lipid metabolism, the adjective "lipidus" appears to be justified. This should remain a subject of current debate and decision by international diabetes institutions. rects excess fat primarily to central depots, and in addition increases the turnover of these depots. This is amplified by a parallel activation of the main trigger of lipolysis in humans, the sympathetic nervous system. The result will be increased concentrations of NEFA, providing substrate to local tissue pools, where excess fat oxidation is interfering with insulin effects. In this way the since long established association between obesity and insulin-resistance diabetes seems to be understandable.
The semantic question posed by Sharir and Raz [1] , requires a final comment. It is very difficult to change an established name of a prevalent disease, a name that has been with us for a long time. Nevertheless, their suggestion is logical. The original name, diabetes mellitus was probably also selected to separate this condition from diabetes incipidus, a problem of minor importance. A suggestion here might be to just skip the "mellitus" and call the condition "diabetes", divided into Type 1 or 2, or whatever new types of diabetes might be discovered.
